Why Home Blood Pressure Monitoring (HBPM) Is More Accurate Than Office BP:
2023 ESH Guidelines + STEP Trial Target BP Science
Every year, hundreds of millions of people worldwide receive an incorrect blood pressure diagnosis — or miss a diagnosis of hypertension that requires treatment. One of the core reasons, surprisingly, is simply where the blood pressure is measured. In 2023, the European Society of Hypertension (ESH) changed the diagnostic landscape with a new set of guidelines. Rather than relying on office blood pressure, the guidelines now formally recommend Home Blood Pressure Monitoring (HBPM) and 24-hour Ambulatory Blood Pressure Monitoring (ABPM) as the first-line standards for hypertension diagnosis.
Around the same time, the STEP trial (Zhang W et al., 2021), published in the New England Journal of Medicine, presented data showing that treating older hypertensive patients to a lower target blood pressure reduces cardiovascular events by 26%. These two developments are fundamentally reshaping the paradigm of hypertension medicine. This article examines the scientific evidence and practical implications with precise data.
PART 1 · Why Office Blood Pressure Is Inaccurate: The Reality of White-Coat Hypertension
1-1. What Is White-Coat Hypertension?
White-Coat Hypertension (WCH) refers to the phenomenon where blood pressure readings are elevated in a hospital or clinic setting (≥140/90 mmHg), yet remain normal in the home or everyday environment. The term "white coat" originates from the observation that merely seeing a physician's or nurse's white coat can trigger anxiety and cause a transient blood pressure rise.
According to the 2023 ESH Guidelines (Mancia G et al., Journal of Hypertension 2023;41(12):1874-2071), approximately 30–40% of patients diagnosed with office hypertension actually have white-coat hypertension. This means that if blood pressure is only measured in a clinical setting, 1 in 3 to 4 diagnosed hypertensive patients may in fact be receiving unnecessary pharmacological treatment.
📊 White-Coat Hypertension Prevalence (2023 ESH Guidelines)
· Proportion of white-coat hypertension among office-diagnosed hypertensives: approximately 30–40%
· Conversely, "Masked Hypertension" also exists — normal in office, elevated at home
· Without HBPM or ABPM, these two conditions cannot be distinguished
· Untreated masked hypertension carries the same target organ damage risk as true hypertension
1-2. The Structural Limitations of Office Blood Pressure
Office blood pressure measurement carries several structural constraints. Patients are already stressed from waiting in the waiting room, and experience another surge of anxiety when entering the consultation room. Only one or two readings are taken, and the recommended 5-minute rest period before measurement is often not adequately observed. In contrast, home blood pressure monitoring uses readings taken by the patient in their most comfortable environment, after sufficient rest, averaged over multiple days. This is far closer to the true long-term average blood pressure.
🏥 Office Blood Pressure
• Single-session, 1–2 readings
• Anxiety and alerting effect present
• Reflects only a specific time of day
• Susceptible to overestimation via white-coat effect
• Misclassification risk in ~30–40% of cases
🏠 Home Blood Pressure (HBPM)
• Multiple readings over 7 days, AM & PM
• Comfortable self-environment
• Captures circadian variation patterns
• White-coat effect eliminated
• Superior predictor of target organ damage
PART 2 · 2023 ESH Guidelines: What Changed
2-1. Key Changes
The European Society of Hypertension's 2023 revised guidelines (Mancia G et al., Journal of Hypertension 2023;41(12):1874-2071) clearly defined the direction for hypertension diagnosis and management as follows.
📋 2023 ESH Guidelines — Core Recommendations
· First-line diagnosis: HBPM and 24-hour ABPM are recommended as the primary standard methods for hypertension diagnosis
· HBPM measurement protocol: Measure twice in the morning (within 1 hour of waking, before medication) and twice in the evening (before bedtime) for 7 days → use the average of all readings excluding the first day (total 24 readings)
· HBPM diagnostic threshold: ≥135/85 mmHg = hypertension (equivalent to office threshold of 140/90 mmHg)
· Target organ damage (TOD) assessment: HBPM is explicitly stated to be superior to office BP for predicting cardiac, renal, and vascular damage
2-2. Age-Specific Blood Pressure Targets (2023 ESH)
The 2023 ESH Guidelines present individualized blood pressure targets stratified by age and comorbidities. The core principle is not "lower is always better" but rather an individualized approach tailored to the patient's characteristics.
| Age Group | SBP Target | DBP Target | Notes |
|---|---|---|---|
| 18–64 years | Below 130 mmHg | Below 80 mmHg | Recommended achievement with pharmacotherapy |
| 65–79 years | 130–139 mmHg | 70–79 mmHg | Below 130 may be considered if tolerated |
| 80 years and older | Individual assessment | Individual assessment | Frailty and fall risk must be considered |
The designation of "individual assessment" for patients aged 80 and older is a meaningful shift. Excessively low blood pressure in this group can reduce cerebral blood flow, increase fall risk, and worsen frailty.
PART 3 · The STEP Trial — Proving New Target BP in Older Hypertensive Patients
3-1. What Is the STEP Trial?
The STEP trial (Systolic Blood Pressure Intervention Trial in Elderly Patients) was a large-scale randomized controlled trial conducted in China, examining whether more intensive blood pressure control improves cardiovascular outcomes in elderly hypertensive patients. Results were published in the New England Journal of Medicine in 2021 (Zhang W et al., NEJM 2021;385(14):1268-1279).
📋 STEP Trial Overview
· Participants: 8,511 hypertensive patients aged 60–80 in China (randomized)
· Intensive treatment group target: Systolic BP (SBP) 110–130 mmHg
· Standard treatment group target: Systolic BP (SBP) 130–150 mmHg
· Follow-up period: Median 3.34 years
· Primary endpoint: Major adverse cardiovascular events (MACE) reduced by 26% in the intensive treatment group
(HR 0.74, 95% CI 0.60–0.92, p=0.007)
3-2. Detailed Results: 33% Reduction in Stroke
The 33% reduction in stroke (HR 0.67) and 33% reduction in acute coronary syndrome in the intensive treatment group (SBP target 110–130 mmHg) demonstrates that achieving a lower blood pressure target offers clear cardiovascular protection even in older patients. It is important to note that this trial enrolled patients aged 60–80, and excluded those with severe frailty or orthostatic hypotension. Before applying the same target to patients aged 80 and above or to frail individuals, consultation with a treating physician is essential.
3-3. The STEP Trial's Significance: The Role of Home Blood Pressure Monitoring
Home blood pressure monitoring played an important role in the STEP trial as a means to confirm blood pressure control. To actually achieve and maintain the intensive treatment target of SBP 110–130 mmHg, clinic visits alone are insufficient. Daily home blood pressure monitoring served as the key tool to verify target attainment in real time and to facilitate communication with physicians.
PART 4 · Why Home BP Better Predicts Target Organ Damage
4-1. Home BP 135/85 = Office BP 140/90
Home blood pressure values cannot be interpreted using the same thresholds as office blood pressure. The 2023 ESH Guidelines specify the following conversion reference values.
📐 Home BP ↔ Office BP Conversion Reference (ESH 2023)
· Home BP 135/85 mmHg ≈ Office BP 140/90 mmHg (hypertension diagnostic threshold)
· Home BP 130/80 mmHg ≈ Office BP 135/85 mmHg
· Home BP averages ~5 mmHg lower than office BP: due to removal of white-coat and activity effects
· Therefore, a consistent home reading at or above 135/85 should be evaluated as hypertension
4-2. Superiority in Predicting Target Organ Damage (TOD)
The reason home BP is superior to office BP is not simply a matter of being in a comfortable environment. Multiple prospective studies consistently demonstrate that home blood pressure is a better predictor of target organ damage (TOD) in the heart, kidneys, and blood vessels than office blood pressure.
Heart (Left Ventricular Hypertrophy)
Home BP shows a stronger correlation with left ventricular mass index (LVMI). Superior to office BP in predicting left ventricular hypertrophy.
Kidneys (Proteinuria / CKD)
Home BP has a higher association with microalbuminuria and chronic kidney disease (CKD) progression. Increasingly used for monitoring kidney protection in treatment.
Vessels (Carotid Intima-Media Thickness)
Carotid intima-media thickness (cIMT) is an early marker of atherosclerosis. Home BP shows a higher predictive correlation with cIMT than office BP.
Brain (Silent Cerebrovascular Lesions)
The association between asymptomatic white matter lesions and home BP has been reported as stronger than the association with office BP.
PART 5 · The 5-Step Correct HBPM Measurement Protocol
The accuracy of home blood pressure monitoring depends not only on the device, but critically on the measurement method. The following 5-step protocol is the standard measurement method based on the 2023 ESH Guidelines.
5-Step Correct HBPM Protocol (Based on ESH 2023)
Rest Quietly for 5 Minutes Before Measuring
Sit quietly for at least 5 minutes before measurement. Avoid caffeine, smoking, and exercise within 30 minutes prior. A full bladder can also elevate blood pressure, so empty it beforehand.
Correct Posture and Cuff Position
Sit with your back supported by a chair and feet flat on the floor. Rest the measuring arm on a support at heart level (mid-chest height). Position the cuff 2–3 cm above the antecubital fossa (inner elbow crease), with enough slack for two fingers to fit underneath.
Take 2 Readings 1–2 Minutes Apart; Record the Average
After the first reading, rest for 1–2 minutes and take a second reading. Record the average of the two as that session's blood pressure. The first reading is almost always higher, so a single measurement alone should be avoided.
One Set Morning and Evening for 7 Days
Morning: Within 1 hour of waking, before taking blood pressure medication, and before breakfast.
Evening: Just before bedtime, in a settled state after dinner.
Measure daily for 7 days (minimum 3 days), and use the average of all readings excluding the first day.
No Talking During Measurement + Record Immediately
Do not speak or move during measurement. Record readings immediately, either manually or via an app. Bluetooth-enabled monitors automatically save and sync data to an app for convenience. Bringing these records to your appointment enables more accurate prescribing decisions.
Practical Guide for Home Blood Pressure Management
- Use a validated upper-arm cuff device: Wrist-type monitors are prone to positional error. Use an upper-arm cuff monitor validated for accuracy by the European Society of Hypertension (ESH) or the British Hypertension Society (BHS).
- Follow the 7-day measurement protocol: For diagnostic purposes, complete a minimum 7-day cycle. For ongoing treatment monitoring, maintain regular 7-day cycles. Do not rely on isolated single readings.
- Remember the home BP threshold: 135/85: The hypertension threshold for home readings differs from the office standard (140/90). Consult your physician if home readings of 135/85 or above occur repeatedly.
- Reference the STEP trial target (ages 60–80): If you are a hypertensive patient aged 60–80, discuss with your physician whether aiming for an SBP target below 130 mmHg may offer cardiovascular benefit in your case.
- Share your data with your doctor: Bring your home BP records to appointments or use your app's PDF report export. The trend over 3–6 months is far more valuable than a single number.
Key References and Data Sources
- Mancia G, Kreutz R, Brunström M, et al. "2023 ESH Guidelines for the Management of Arterial Hypertension." Journal of Hypertension. 2023;41(12):1874-2071.
- Zhang W, Zhang S, Deng Y, et al. "Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP)." New England Journal of Medicine. 2021;385(14):1268-1279.
- Stergiou GS, Palatini P, Parati G, et al. "2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement." Journal of Hypertension. 2021;39(7):1293-1302.
- Parati G, Stergiou G, Dolan E, Bilo G. "Blood pressure variability: clinical relevance and application." Journal of Clinical Hypertension. 2018;20(7):1133-1137.
- Niiranen TJ, Hanninen MR, Johansson J, Reunanen A, Jula AM. "Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home study." Hypertension. 2010;55(6):1346-1351.
- World Health Organization. Global Report on Hypertension: The Race Against a Silent Killer. Geneva: WHO; 2023.
Frequently Asked Questions (FAQ)
Why is it important to measure blood pressure in the morning?
Blood pressure rises most sharply immediately after waking — a phenomenon called the "Morning Surge." This is directly linked to the higher incidence of stroke and myocardial infarction between 6 a.m. and noon. Measuring before taking blood pressure medication also allows an indirect assessment of the medication's duration of action — comparing pressure when the drug is still active versus when it has worn off.
My home BP reads high but I have no symptoms. Do I still need treatment?
Hypertension is known as the "silent killer" precisely because it causes no symptoms in the vast majority of cases. Even without symptoms, persistently elevated blood pressure quietly accumulates damage to blood vessels, the heart, kidneys, and brain. If home readings of 135/85 mmHg or above occur repeatedly, consulting your physician to evaluate the need for treatment is recommended, regardless of how you feel.
How does smartwatch blood pressure differ from a home BP monitor?
Most current smartwatches use a PPG (photoplethysmography) sensor, which has lower absolute measurement accuracy than cuff-based oscillometric methods. Both the American Heart Association (AHA) and ESH acknowledge smartwatch blood pressure as useful for tracking blood pressure "trends," but recommend that validated cuff-type monitors be used for all diagnostic and treatment decisions.
Do the STEP trial results apply to non-Chinese populations?
The STEP trial enrolled 8,511 patients from China. East Asian populations have a higher proportion of stroke relative to coronary artery disease compared to Western populations, but the cardiovascular protective effect of blood pressure control is generally considered applicable across ethnicities. Direct application to Korean or other Asian populations still requires the judgment of a treating physician.